Last reviewed · How we verify
Lidoderm 5% patch
Lidocaine delivered transdermally blocks sodium channels in nerve fibers to provide localized pain relief.
Lidocaine patches deliver local anesthetic directly to the skin to block nerve signals and reduce pain sensation in the affected area. Used for Post-herpetic neuralgia (PHN), Localized neuropathic pain.
At a glance
| Generic name | Lidoderm 5% patch |
|---|---|
| Sponsor | Nicole K Brogden |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Neurology |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that penetrates the skin when applied as a patch and reversibly blocks voltage-gated sodium channels in sensory nerve fibers, preventing the initiation and conduction of nerve impulses. This results in localized anesthesia and pain relief in the area of application without significant systemic absorption. The patch formulation allows for sustained, controlled delivery of lidocaine to the affected area.
Approved indications
- Postherpetic neuralgia (localized pain relief)
- Localized neuropathic pain
Common side effects
- Skin irritation or erythema at application site
- Dermatitis or allergic contact dermatitis
- Burning or stinging at application site
- Edema at application site
Key clinical trials
- Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
- Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department (PHASE4)
- Frozen Shoulder and Hormone Replacement Therapy (PHASE4)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Connective Tissue Matrix for Rotator Cuff Tendinopathy (PHASE4)
- The Comparison of Navigational Bronchoscopic and CT-Guided Preoperative Markings in Minimally Invasive Thoracic Surgery (NA)
- The OBstetric Lidocaine Patch (OBLido) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidoderm 5% patch CI brief — competitive landscape report
- Lidoderm 5% patch updates RSS · CI watch RSS
- Nicole K Brogden portfolio CI